. 2010 Sep 17;107(37):647–656. doi: 10.3238/arztebl.2010.0647

Table 4. Evidence levels (from 1 = high to 5 = low) and recommendation strengths (from A = strong to C = weak) for the treatment of comorbidity in chronic renal insufficiency^*1.

Condition	Treatment	Evidence level and recommendation strength	References
Sodium retention	Diuretics	3A	(13, e17)
Target Hb 10 rather than 12–13 g/dL	Epo	1A	(14, e4– e6, e18)
Inadequate iron resorption	Iron IV	1A	(15, e19)
1a-hydroxylase deficiency	Calcitriol	2C	(16, e20)
Hyperparathyroidism	Paricalcitol	3C	(e7, e20)
Hyperparathyroidism	Cinacalcet	1B	(e7, e21)
Neutralization of acidosis	Bicarbonate	3B	(17, e22)
Ca × PO₄-product	Sevelamer	2B	(e7, e23)
Ca × PO₄-product	Lanthanum	3C	(e7, e23)

^*1Some of the Cochrane Reviews and Cochrane Meta-Analyses cited (e18, e20, e22) do not consider the more recent studies (e4– e6, 16, 17)

Table 4. Evidence levels (from 1 = high to 5 = low) and recommendation strengths (from A = strong to C = weak) for the treatment of comorbidity in chronic renal insufficiency*1.